Helmut Pürerfellner1, Prashanthan Sanders2, Evgeny Pokushalov3, Marco Di Bacco4, Tracy Bergemann5, Lukas R C Dekker6. 1. Department of Cardiology, Elisabethinen University Teaching Hospital, Linz, Austria. Electronic address: helmut.puererfellner@elisabethinen.or.at. 2. Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia. 3. Arrhythmia Department, State Research Institute of Circulation Pathology, Novosibirsk, Russia. 4. Medtronic Bakken Research Center BV, Maastricht, the Netherlands. 5. Medtronic, Inc, Minneapolis, Minnesota. 6. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Abstract
BACKGROUND: The Reveal LINQ is a miniaturized insertable cardiac monitor (ICM) with wireless telemetry for remote monitoring of patients with suspected arrhythmias. OBJECTIVE: The primary objective of this study was to evaluate the functionality of the Reveal LINQ system by measuring R-wave sensing and data transmission. METHODS: The Reveal LINQ Usability Study was a nonrandomized, prospective, multicenter trial. The study enrolled 30 patients with any indication for an ICM. Data were collected at baseline, implantation, and 1-month follow-up visits and through daily wireless transmissions. RESULTS: Thirty patients were enrolled and had a Reveal LINQ device implanted. The mean age was 55 ± 15 years. All patients had successful implantation of the ICM in one of the recommended locations. Ease of implantation procedure was rated as easy or very easy for 90% of implantations. R-wave amplitudes were 0.584 ± 0.325 mV at implantation and 0.596 ± 0.336 mV at 1 month (P = .8). Automatic transmissions were successful 79.5% (69.5%-86.9%) of the time. Transmission failures that caused a delay in data transfer occurred because of incomplete data reception or patients being out of range in 45% and 42% of instances, respectively. For all patients, transmission failures were followed by successful automated or manual transmission of information on a subsequent day. The devices stored 217 arrhythmic episodes during 30 days of follow-up, identified as atrial fibrillation (n = 111), asystole (n = 95), bradycardia (n = 4), fast ventricular tachycardia (n = 1), and ventricular tachycardia ( n = 6). No serious procedure- or system-related adverse events occurred during the 1-month follow-up period. CONCLUSION: The miniaturized Reveal LINQ ICM supports arrhythmia detection and monitoring, achieving adequate sensing performance without safety issues. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01965899.
BACKGROUND: The Reveal LINQ is a miniaturized insertable cardiac monitor (ICM) with wireless telemetry for remote monitoring of patients with suspected arrhythmias. OBJECTIVE: The primary objective of this study was to evaluate the functionality of the Reveal LINQ system by measuring R-wave sensing and data transmission. METHODS: The Reveal LINQ Usability Study was a nonrandomized, prospective, multicenter trial. The study enrolled 30 patients with any indication for an ICM. Data were collected at baseline, implantation, and 1-month follow-up visits and through daily wireless transmissions. RESULTS: Thirty patients were enrolled and had a Reveal LINQ device implanted. The mean age was 55 ± 15 years. All patients had successful implantation of the ICM in one of the recommended locations. Ease of implantation procedure was rated as easy or very easy for 90% of implantations. R-wave amplitudes were 0.584 ± 0.325 mV at implantation and 0.596 ± 0.336 mV at 1 month (P = .8). Automatic transmissions were successful 79.5% (69.5%-86.9%) of the time. Transmission failures that caused a delay in data transfer occurred because of incomplete data reception or patients being out of range in 45% and 42% of instances, respectively. For all patients, transmission failures were followed by successful automated or manual transmission of information on a subsequent day. The devices stored 217 arrhythmic episodes during 30 days of follow-up, identified as atrial fibrillation (n = 111), asystole (n = 95), bradycardia (n = 4), fast ventricular tachycardia (n = 1), and ventricular tachycardia ( n = 6). No serious procedure- or system-related adverse events occurred during the 1-month follow-up period. CONCLUSION: The miniaturized Reveal LINQ ICM supports arrhythmia detection and monitoring, achieving adequate sensing performance without safety issues. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01965899.
Authors: David D McMANUS; Jo Woon Chong; Apurv Soni; Jane S Saczynski; Nada Esa; Craig Napolitano; Chad E Darling; Edward Boyer; Rochelle K Rosen; Kevin C Floyd; Ki H Chon Journal: J Cardiovasc Electrophysiol Date: 2015-11-13
Authors: Michael Gruska; Gerhard Aigner; Johann Altenberger; Dagmar Burkart-Küttner; Lukas Fiedler; Marianne Gwechenberger; Peter Lercher; Martin Martinek; Michael Nürnberg; Gerhard Pölzl; Gerold Porenta; Stefan Sauermann; Christoph Schukro; Daniel Scherr; Clemens Steinwender; Markus Stühlinger; Alexander Teubl Journal: Wien Klin Wochenschr Date: 2020-12-01 Impact factor: 1.704
Authors: Ralph J Damiano; Christopher P Lawrance; Lindsey L Saint; Matthew C Henn; Laurie A Sinn; Jane Kruse; Marye J Gleva; Hersh S Maniar; Patrick M McCarthy; Richard Lee Journal: Ann Thorac Surg Date: 2015-10-24 Impact factor: 4.330
Authors: Karlien J Ter Meulen; Ben J M Hermans; Frank M van der Sande; Bernard Canaud; Constantijn J A M Konings; Jeroen P Kooman; Tammo Delhaas Journal: Sci Rep Date: 2021-05-10 Impact factor: 4.379
Authors: Gregory W Albers; Richard A Bernstein; Johannes Brachmann; John Camm; J Donald Easton; Peter Fromm; Shinya Goto; Christopher B Granger; Stefan H Hohnloser; Elaine Hylek; Amir K Jaffer; Derk W Krieger; Rod Passman; Jesse M Pines; Shelby D Reed; Peter M Rothwell; Peter R Kowey Journal: J Am Heart Assoc Date: 2016-03-15 Impact factor: 5.501